Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNACFree Report) in a research report released on Thursday morning,Benzinga reports. They currently have a $41.00 price objective on the stock.

A number of other research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Cartesian Therapeutics in a report on Tuesday, January 28th. BTIG Research assumed coverage on Cartesian Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Cantor Fitzgerald raised Cartesian Therapeutics to a “hold” rating in a report on Monday, December 2nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.86.

Check Out Our Latest Stock Report on Cartesian Therapeutics

Cartesian Therapeutics Stock Down 5.0 %

NASDAQ:RNAC opened at $16.61 on Thursday. The business’s 50-day moving average price is $18.60 and its 200 day moving average price is $18.68. The firm has a market cap of $422.14 million, a P/E ratio of -0.31 and a beta of 0.71. Cartesian Therapeutics has a 52-week low of $11.67 and a 52-week high of $41.87.

Insider Buying and Selling

In related news, CFO Blaine Davis sold 4,028 shares of Cartesian Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $16.83, for a total value of $67,791.24. Following the transaction, the chief financial officer now owns 94,811 shares of the company’s stock, valued at approximately $1,595,669.13. This trade represents a 4.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CTO Metin Kurtoglu sold 2,417 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $16.72, for a total value of $40,412.24. Following the sale, the chief technology officer now owns 64,716 shares of the company’s stock, valued at $1,082,051.52. The trade was a 3.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,744 shares of company stock valued at $247,337. 57.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cartesian Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Cartesian Therapeutics by 22.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,562 shares of the company’s stock worth $82,000 after acquiring an additional 847 shares during the period. BNP Paribas Financial Markets boosted its position in Cartesian Therapeutics by 122.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company’s stock worth $27,000 after acquiring an additional 909 shares during the period. Rhumbline Advisers boosted its position in Cartesian Therapeutics by 10.0% during the 4th quarter. Rhumbline Advisers now owns 10,201 shares of the company’s stock worth $183,000 after acquiring an additional 927 shares during the period. Corebridge Financial Inc. boosted its position in Cartesian Therapeutics by 32.6% during the 4th quarter. Corebridge Financial Inc. now owns 5,122 shares of the company’s stock worth $92,000 after acquiring an additional 1,258 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Cartesian Therapeutics by 44.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,786 shares of the company’s stock worth $104,000 after acquiring an additional 1,789 shares during the period. 86.95% of the stock is currently owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

(Get Free Report)

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

Recommended Stories

Analyst Recommendations for Cartesian Therapeutics (NASDAQ:RNAC)

Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.